Canonical text (the exact bytes fingerprinted)

TRUVACE RECORD VERSION
record: TRV-2026-0039
version: 2
kind: revised
reason: Model backfill: grounded claim, summary, sector, and trace validation
timestamp: 2026-07-13T00:40:47.862356Z
status: published
lens: p_space
sector: health
headline: Linq ii¿ insertable cardiac monitor: FDA malfunction report involving AI
dek: The FDA received a malfunction report involving Linq ii¿ insertable cardiac monitor, made by Medtronic singapore operations. It was reported that true pause episodes were rejected as false by the artificial intelligence (ai) algorithm. it was further reported that the implantable cardiac monitor (icm) detected false ventricular tachycardia (vt) episodes. the icm remains in use. no patient complications have been reported as a result of this event.
gain_title: (none)
problem_title: An FDA malfunction report described the Linq II insertable cardiac monitor's AI algorithm rejecting true pause episodes and generating false ventricular tachycardia detections, with no complications reported to date.
trace_subject: (none)
gain_reading: (none)
problem_reading: An FDA malfunction report described the Linq II insertable cardiac monitor's AI algorithm rejecting true pause episodes and generating false ventricular tachycardia detections, with no complications reported to date.
quick_read: The FDA received a malfunction report for the Linq ii insertable cardiac monitor made by Medtronic singapore operations. According to the report, the device's AI algorithm rejected true pause episodes as false and detected false ventricular tachycardia episodes. The monitor remains implanted and in use, and the report states no patient complications have been reported as a result of this event.

Accurate pause and tachycardia detection matters because clinicians rely on these classifications for diagnosis and management decisions, so missed true events and false alerts could affect care if confirmed. What remains uncertain is whether this single report reflects a systematic issue, as the text notes it is part of MAUDE surveillance and should be read as a signal for follow-up, not a clinical conclusion or verified incidence rate, and causality is not established.
limitation: Single MAUDE malfunction report; does not establish causality, incidence rate, or clinical outcome impact.
tag: Evidence-backed problem
key_points: Device identified as Linq ii insertable cardiac monitor made by Medtronic singapore operations. | Report states the icm remains in use after the reported malfunction. | Report states no patient complications have been reported as a result of this event. | Source notes the report is part of FDA's MAUDE surveillance data and should be read as a signal for follow-up.
rundown: The FDA received a malfunction report for the Linq ii insertable cardiac monitor made by Medtronic singapore operations. According to the report, the device's AI algorithm rejected true pause episodes as false and detected false ventricular tachycardia episodes. The monitor remains implanted and in use, and the report states no patient complications have been reported as a result of this event.

Accurate pause and tachycardia detection matters because clinicians rely on these classifications for diagnosis and management decisions, so missed true events and false alerts could affect care if confirmed. What remains uncertain is whether this single report reflects a systematic issue, as the text notes it is part of MAUDE surveillance and should be read as a signal for follow-up, not a clinical conclusion or verified incidence rate, and causality is not established.
sources:
- government | FDA MAUDE report 25093688 | https://api.fda.gov/device/event.json?search=mdr_report_key%3A%2225093688%22&sort=date_received%3Adesc&limit=1 | 2026-05-06
prev: b2cf1d3d9add489db66c7d9e8f7da6c17040431df399259cd530d865849cf462

sha256

1af519f01989ef2de4ee992bde3755c202707430292bc1e381c7c59ebefbb495

previous

b2cf1d3d9add489db66c7d9e8f7da6c17040431df399259cd530d865849cf462